购物车
  • TargetMol
    您的购物车当前为空

Raltegravir

Synonyms: 雷特格韦, MK-0518
货号 T2239LCas号 518048-05-0 一键复制产品信息纯度: 99.89%
Rating icon 很棒

Raltegravir (MK-0518) 是一种HIV 整合酶抑制剂。

Raltegravir

一键复制产品信息
Rating icon 很棒

纯度: 99.89%

货号 T2239LCas号 518048-05-0

别名 雷特格韦, MK-0518

Raltegravir (MK-0518) 是一种HIV 整合酶抑制剂。

Raltegravir
其他形式的 “Raltegravir”:
规格价格库存数量
1 mg
¥ 262
现货
5 mg
¥ 567
现货
10 mg
¥ 937
现货
25 mg
¥ 1,720
现货
50 mg
¥ 2,880
现货
100 mg
¥ 3,970
现货
200 mg
¥ 5,790
现货
1 mL x 10 mM (in DMSO)
¥ 637
现货
库存状态实时更新,以官网显示为准,现货产品可直接加购物车下单
大包装 & 定制
加入购物车

TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

实验操作小课堂
常见问题解答
查看更多

选择批次:
纯度: 99.89%
颜色: 白色
资源下载: COA LCMS HPLC HNMR产品操作手册

产品介绍


生物活性
产品描述
Raltegravir (MK-0518) is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.
靶点活性
Integrase (WT PFV):90 nM, Integrase (S217Q PFV):40 nM
体外活性

Raltegravir诱导非人灵长类病毒的免疫学改善,并伴有进展性SIVmac251感染.

体内活性

Raltegravir在体外作用于人类T淋巴细胞培养物,有效作用于HIV-1,抑制达95%时浓度为31±20 nM。S217Q PFV IN对Raltegravir的敏感性至少与WT酶相似。在急性感染的人类淋巴CD4 + T细胞系MT-4和CEMx174中,Raltegravir高效抑制SIVmac251复制,EC90处于低纳摩尔范围。Raltegravir微弱抑制肝细胞色素P450。Raltegravir不会诱导CYP3A4 RNA表达或CYP3A4依赖的睾丸激素6-β-羟化酶活性。Raltegravir在镁和钙存在时,细胞扩散性降低。Raltegravir和相关的HIV-1整合酶链转移抑制剂高效阻断病毒复制。

激酶实验
PFV integration assay: For quantitative strand transfer assays, donor DNA substrate is formed by annealing HPLC grade oligonucleotides 5′-GACTCACTATAGGGCACGCGTCAAAATTCCATGACA and 5′-ATTGTCATG GAATTTTGACGCGTGCCCTATAGTGAGTC. Reactions (40 μL) contains 0.75 μM PFV IN, 0.75 μM donor DNA, 4 nM (300 ng) supercoiled pGEM9-Zf(?) target DNA, 125 mM NaCl, 5 mM MgSO4, 4 μM ZnCl2, 10 mM DTT, 0.8% (vol/vol) DMSO, and 25 mM BisTris propane–HCl, pH 7.45. Raltegravir is added at indicated concentrations. Reactions are initiated by addition of 2 μL PFV IN diluted in 150 mM NaCl, 2 mM DTT, and 10 mM Tris-HCl, pH 7.4, and stopped after 1 hour at 37 °C by addition of 25 mM EDTA and 0.5% (wt/vol) SDS. Reaction products, deproteinized by digestion with 20 μg proteinase K for 30 minutes at 37 °C followed by ethanol precipitation, are separated in 1.5% agarose gels and visualized by staining with ethidium bromide. Integration products are quantified by quantitative real-time PCR, using Platinum SYBR Green qPCR SuperMix and three primers: 5′-CTACTTACTCTAGCTTCCCGGCAAC, 5′-TTCGCCAGTTAATAGTTTGCGCAAC, and 5′-GACTCACTATAGGGCACGCGT. PCR reactions (20 μL) contained 0.5 μM of each primer and 1 μL diluted integration reaction product. Following a 5-min denaturation step at 95 °C, 35 cycles are carried out in a CFX96 PCR instrument, using 10 seconds denaturation at 95 °C, 30 seconds annealing at 56 °C and 1 minutes extension at 68 °C. Standard curves are generated using serial dilutions of WT PFV IN reaction in the absence of INSTI.
细胞实验
Human MT-4 cells are infected for 2 hours with the SIVmac251, HIV-1 (IIIB) and HIV-2 (CDC 77618) stocks at a multiplicity of infection of, approximately, 0.1. Cells are then washed three times in phosphate buffered saline, and suspended at 5 × 105/mL in fresh culture medium (to primary cells 50 units/mL of IL-2 are added) in 96-well plates, in the presence or absence of a range of triplicate raltegravir concentrations (0.0001 μM -1 μM). Untreated infected and mock-infected controls are prepared too, in order to allow comparison of the data derived from the different treatments. Viral cytopathogeniciy in MT-4 cells is quantitated by the methyl tetrazolium (MTT) method (MT-4/MTT assay) when extensive cell death in control virus-infected cell cultures is detectable microscopically as lack of capacity to re-cluster. The capability of MT-4 cells to form clusters after infection. Briefly, clusters are disrupted by pipetting; and, after 2 hours of incubation at 37 °C, the formation of new clusters is assessed by light microscopy (100 × magnification). Cell culture supernatants are collected for HIV-1 p24 and HIV-2/SIVmac251 p27 core antigen measurement by ELISA. In CEMx174-infected cell cultures, which show a propensity to form syncytia induced by the virus envelope glycoproteins, syncytia are counted, in blinded fashion, by light microscopy for each well at 5 days following infection. (Only for Reference)
别名
雷特格韦, MK-0518
化学信息
分子量444.42
分子式C20H21FN6O5
CAS No.518048-05-0
SmilesCc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C
密度1.46 g/cm3
储存&溶解度
存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

实际储存温度请以COA为准

溶解度信息
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 250 mg/mL (562.53 mM), Sonication is recommended.
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.25 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM2.2501 mL11.2506 mL22.5012 mL112.5062 mL
5 mM0.4500 mL2.2501 mL4.5002 mL22.5012 mL
10 mM0.2250 mL1.1251 mL2.2501 mL11.2506 mL
20 mM0.1125 mL0.5625 mL1.1251 mL5.6253 mL
50 mM0.0450 mL0.2250 mL0.4500 mL2.2501 mL
100 mM0.0225 mL0.1125 mL0.2250 mL1.1251 mL
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSOPEG300PEG400Tween 80SBE-β-CD玉米油等, 均可在TargetMol网站点击购买。
1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

Related Tags: buy Raltegravir | purchase Raltegravir | Raltegravir cost | order Raltegravir | Raltegravir chemical structure | Raltegravir in vivo | Raltegravir in vitro | Raltegravir formula | Raltegravir molecular weight